Dr. Jeanette Wood Joins Nuevolution
News Sep 22, 2015
Nuevolution A/S has announced that Dr. Jeanette Wood has joined Nuevolution’s board of directors and will furthermore serve as scientific advisor to the board.
“We are very pleased that Dr. Jeanette Wood has accepted to join us as Director and Scientific Advisor,” said Alex Gouliaev, CEO of Nuevolution A/S and continued “Jeanette has extensive experience in all aspects of drug discovery from target validation, lead optimization, biomarker development, through to translational research in support of clinical trials as well as experience in multiple therapeutic areas. Her extensive expertise and experience will strongly support Nuevolution in successfully developing its pipeline within oncology, inflammation and immuno-oncology.”
Jeanette Wood, Ph.D. is presently CSO at Swiss-based biotech company Genkyotex. In this role she is responsible for the NOX enzyme platform, and the discovery and early development portfolio.
Born and educated in New Zealand (PhD in Pharmacology from University of Otago, Dundein, New Zealand), Jeanette began her drug discovery career in the cardiovascular area in Ciba-Geigy in Switzerland. Early research was focused on innovative small molecule drugs targeting the renin-angiotensin system and later, in Novartis, on anti-angiogenesis therapies for cancer and inflammatory diseases.
In both the cardiovascular and cancer areas, Jeanette successfully led various global drug discovery teams and research groups and she played a major role in the discovery and/or profiling of several marketed drugs and compounds in the Novartis development portfolio. Jeanette left Novartis to join Singapore-based S*BIO, as Head of Biology.
Under her leadership, 6 novel compounds targeting HDAC, JAK2, CDK, mTOR and PI3K were discovered and selected for development as new therapies for cancer and autoimmune diseases, of which 4 programs entered and are still progressing in clinical development.
Before joining Genkyotex, Jeanette held a senior management positions at AstraZeneca where she was responsible for the early discovery portfolio within oncology including biology, chemistry and DMPK functions to support both the research and development portfolios.
Jeanette is author of numerous scientific publications and patents and has served as an Adjunct Professors at Universities in Basel, Singapore and Korea.
Nuevolution’s Board of Directors is composed as follows:
• Stig Løkke Pedersen, Chairman of the Board.
• Viktor Drvota, Director, SEB Venture Capital, Head of Investment Area, Life Science.
• Søren Lemonius, Director, Partner, Sunstone Capital.
• Lars Henriksson, Director, Investment Manager, Industrifonden.
• Professor Dr. Jutta Heim, Director, Senior Scientific Advisor to the Board
• Dr. Jeanette Wood, Director, Senior Scientific Advisor to the Board
• Stefan Olofsson, Observer, SEB Venture Capital Investment Manager, Life Science and Technology
Stig Løkke Pedersen, Chairman of Nuevolution A/S said: “Nuevolution has successfully developed and commercialized its Chemetics® technology to a very advanced level, and is progressing its own programs within oncology, inflammation and immuno-oncology. We are convinced that Jeanette’s expertise in drug discovery and drug development will add further important expertise to the Board of Directors.”
“I am excited to join Nuevolution as Board Member and Scientific Advisor”, Jeanette Wood commented. “Nuevolution has a very powerful proprietary discovery engine that can be applied to attractive but difficult drug targets in areas of high unmet medical need. My experience and competencies really complement very strong management and board teams. I look forward to helping advance some very novel drug candidates as well as the commercial success of this innovative company.”
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE